{
    "Case ID": "060193",
    "Different Crime": [
        {
            "Crime Name": "unknown",
            "Crime Type": "others",
            "legal_basis": [
                "Section 8 of the PM (NOC) Regulations"
            ],
            "application_details": [
                "Teva argued that its losses should be assessed from July 18, 2003",
                "Teva's Form V acknowledgment and other regulatory factors"
            ],
            "decision_reasoning": [
                "The Relevant Period could not begin before the statutory stay commenced",
                "December 13, 2005, as the more appropriate start date"
            ],
            "evidence_presented": [
                "regulatory framework",
                "expert testimonies",
                "factual evidence"
            ],
            "result_of_case": [
                "Teva was awarded damages based on a calculated market share",
                "excluding claims for 'lost business value' and 'duplicate ramp-up'"
            ],
            "cause_of_action": [
                "Sanofi's actions under the PM (NOC) Regulations delayed Teva's market entry for ramipril"
            ]
        }
    ]
}